Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover.
The development of new biochemical markers has made it possible to assess the effects of therapeutic agents on bone turnover more rapidly and precisely. In this early phase II study, we analyzed the effects of short-term, high-dose treatment with risedronate, a potent pyridinyl bisphosphonate, on markers of bone resorption and formation. Resorption markers included urinary free deoxypyridinoline (D-Pyr) crosslinks, N-terminal telopeptide (NTx) and C-terminal telopeptide (CTx) type I collagen crosslinks. Bone formation markers included osteocalcin (OC), bone-specific alkaline phosphatase (BSAP) and the C-terminal peptide of type I procollagen (PICP). All three resorption markers showed rapid, significant (p<0.05) decreases from baseline following daily administration of 30 mg risedronate for 2 weeks. The mean decreases at 2 weeks were 28% for D-Pyr, 61% for NTx and 73% for CTx, respectively. Over the next 10 weeks after treatment, D-Pyr approached baseline while NTx and CTx remained well below baseline values. The markers of bone formation showed little change during therapy but decreased significantly at 4-10 weeks after therapy - an expected outcome of bisphosphonate therapy. Moreover, there was a significant correlation between the early effects on bone resorption markers and the delayed effects on formation markers. This study demonstrates that the approved dose of risedonate (30 mg/day) for Paget's disease is effective at decreasing bone turnover after 2 weeks of treatment, as observed by the sensitive response of bone turnover markers.
Raisz
L
L
Division of Endocrinology/Metabolism, University of Connecticut Health Center, Farmington 06032, USA. Raisz@nso.uchc.edu
Smith
J A
JA
Trahiotis
M
M
Fall
P
P
Shoukri
K
K
Digennaro
J
J
Sacco-Gibson
N
N
D000469:Alkaline Phosphatase / Q000652:urine; D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000652:urine*; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D015331:Cohort Studies; D003094:Collagen / Q000652:urine; D024042:Collagen Type I; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000652:urine; D010455:Peptides / Q000652:urine; D017698:Postmenopause; D011347:Procollagen / Q000652:urine; D000068296:Risedronic Acid
D000596:Amino Acids; D015415:Biomarkers; D002121:Calcium Channel Blockers; D024042:Collagen Type I; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; C036020:deoxypyridinoline; D003094:Collagen; D000469:Alkaline Phosphatase; D000068296:Risedronic Acid; D012968:Etidronic Acid